Amyloid and Neurodegeneration Have Different Underlying Genetics
Different genetic factors underlie amyloid accumulation and atrophy, researchers at AAIC reported.
6404 RESULTS
Sort By:
Different genetic factors underlie amyloid accumulation and atrophy, researchers at AAIC reported.
Increasingly, people must learn of their amyloid status and/or ApoE genotype in order to enter secondary prevention trials. At AAIC, researchers laid out their procedures to ethically break the news.
Read our full coverage of this year’s AAIC conference.
Parabiosis passes its first test in mouse models of Alzheimer’s, normalizing gene expression and improving memory—though with no reduction in amyloid plaques.
Researchers explain why the protease cuts at every third amino acid, shedding light on how some familial APP mutations are pathogenic.
With a laser focus on biomarkers and disease mechanisms, researchers at the 10th ICFTD meeting prepared the ground for therapeutic studies.
Frontotemporal Dementia: The Hard Work of Pushing Toward Trials First Round of FTD Therapeutics Fell Short, But Many More Are Up and Running Fluid NfL Shines, Tau PET Dims, in the Hunt for FTD Biomarkers Tests of Social Cognition Hold Potential as FTD Out
Researchers reported negative findings from three trials at ICFTD 2016.
Researchers at an international frontotemporal dementia congress reported progress in finding markers that track disease, but no luck thus far with diagnostic markers.
Several such tests generated enthusiasm at the international frontotemporal dementia congress.
Geneticists at frontotemporal dementia conference reported a new link with a ubiquitine enzyme and strengthened other gene associations.
Sometimes challenged, the idea that pathogenic proteins spread through the brain got a lift from new animal model data presented at the frontotemporal dementia meeting.
Idalopirdine failed to slow memory decline in patients with Alzheimer’s disease.
In mice, rolofylline perks up neurons laid low by aggregates of tau.
Can sucking in a little extra drug tide patients over until their next dose?